

# WHO Costing, Budgeting, Financing and Delivery of COVID-19 Vaccines

Q&A for Session 07: Regional approach to support COVID-19 vaccination costing and budgeting in countries in the Americas and Europe

Wednesday, September 15, 2021

Thank you for attending the above webinar session. Many questions were submitted by participants during the webinar. In this document, we share the answers from presenters to each question that was asked during the corresponding Q&A session.

Links to the session recordings in all languages and presentations can be found on the [TechNet-21 website](#).

More information on COVID-19 vaccine introduction can be found in the resources listed below.

- COVID-19 vaccine introduction toolkit in [English](#), [Arabic](#), [Chinese](#), [French](#), [Russian](#), and [Spanish](#).
- [Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines](#)
- [TechNet-21 – The Technical Network for Strengthening Immunization Services](#)

Webinar-related resources can be found in the following links:

- COVID-19 Vaccine Introduction and deployment Costing tool (CVIC tool): [https://www.who.int/publications/i/item/who-2019-ncov-vaccine\\_deployment\\_tool-2021.1](https://www.who.int/publications/i/item/who-2019-ncov-vaccine_deployment_tool-2021.1)
- COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool course on OpenWHO: <https://openwho.org/courses/cvic-tool>
- Costs of delivering COVID-19 vaccine in 92 AMC countries: <https://www.who.int/publications/m/item/costs-of-delivering-covid-19-vaccine-in-92-amc-countries>
- Immunization economics website: <https://immunizationeconomics.org/ican-idcc>

In addition, TechNet-21 manages two Telegram channels supporting the webinar series participants. In these spaces you will be able to share your experiences, discuss key questions, and connect with experts from around the world. We'll also share new information and global guidance as it becomes available.

Join us today:

- [WHO Costing, Budgeting, Financing and Delivery of COVID-19 Vaccines](#) (EN)
- [OMS - calcul des coûts, budgétisation, financement et livraison des vaccins COVID-19](#) (FR)

**How is the CVIC tool addressing the short shelf-life of vaccine, the supply uncertainties, the type and schedule of the vaccine?**

Live answered at 21:48 - <https://youtu.be/GQuTXNVSKI?t=1308>

**Is the CVIC tool used to cost COVID-19 initial plans only? Or can it be used later on after the vaccination plan?**

Live answered at 25:05 - <https://youtu.be/GQuTXNVSKI?t=1505>

All estimations can be updated as more information comes available.

**You mentioned that there's a local motivation of in-country stakeholders to use the CVIC tool. How did you get the country convinced to use this tool, and since you are experiencing CVIC and knowing the country so well, what do you think the needs of the country are regarding the costing tool or in the costing process?**

Live answered at 26:11 - <https://youtu.be/GQuTXNVSKI?t=1571>

**When was this tool designed? Was it designed by WHO only?**

Live answered at 28:32 - <https://youtu.be/GQuTXNVSKI?t=1712>

The tool was initially developed by WHO colleagues in EMRO end of 2020 and later on reviewed and further developed by other WHO colleagues and costing experts outside WHO. The tool is aligned with the NDVP and with the Partners Platform.

**Is this tool used/needed in countries that have UHC?**

Live answered at 29:26 - <https://youtu.be/GQuTXNVSKI?t=1766>

**Can you please share results of the costing exercises conducted by other countries?**

This current presentation should show some results from the NDVP analysis. In the later session on 13 Oct 2021, our SEARO colleagues will also present some results of the analysis.

**I want to know about sensitization on vaccines and how are statistics playing a role in having a number of people ready to be vaccinated.**

The NDVP helps with planning on sensitization and mobilization of COVID-19 vaccination. The CVIC tool is aligned with NDVP and helps to cost out the sensitization activities.

**As you mentioned, some cost drivers may be absent in the budget, such as human resources, some outreach delivery, and also most of the plans were until 2021. Are you aware if any country in the Americas is going to cost for 2022 or further or to include the best cost drivers? What's your advice on this?**

Live answered at 55:14 - <https://youtu.be/GQuTXNVSKI?t=3314>

**Do we really need to advocate that the funding should quickly migrate to the normal funding mechanism like the federal budget? Because this will increase the proportion of the Health budget relative to other sectors which might result to some pushbacks from other sectors? It might also affect the quick draw down of these funds and even ability to mobilise adequate amount needed.**

If vaccination against COVID-19 becomes part of the regular annual vaccination schemes, then financing for these plans should be secured as part of the annual health budgets and in particular as part of the national immunization programmes avoiding the creation of a new special programme. Pushbacks from other sectors in terms of funding can also be avoided by inclusion within the regular budget, instead of some form of discretionary spending. In terms of mobilizing the adequate amounts it is crucial to prepare these budgets with the best information at hand and on technically sound basis, for which the CVIC tool can be very useful.